{"id":483686,"date":"2020-05-11T15:06:02","date_gmt":"2020-05-11T15:06:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483686"},"modified":"2020-05-11T15:06:02","modified_gmt":"2020-05-11T15:06:02","slug":"huntington-disease-pipeline-insights-upcoming-therapies-in-the-huntington-disease-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/huntington-disease-pipeline-insights-upcoming-therapies-in-the-huntington-disease-market_483686.html","title":{"rendered":"Huntington disease Pipeline Insights : Upcoming therapies in the Huntington disease Market"},"content":{"rendered":"
\"Huntington<\/a><\/p>\n
\n
Huntington disease Pipeline Insights <\/p>\n<\/div>\n<\/div>\n<\/div>\n
RG6042 by Roche, Neflamapimod under development by Vertex and EIP pharma, Pepinemab of Vaccinex, SOM3355 of OM Biotech SL and ALZ002 of Allianz Pharma are some of the emerging pipeline products in the Huntington\u2019s disease market.<\/div>\n

“Huntington’s Disease Pipeline Insight, 2020<\/a><\/strong>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Huntington’s Disease market.<\/p>\n

Study Period<\/strong>: 2017-2030<\/p>\n

Disease Overview<\/strong><\/p>\n

Huntington disease (HD) is an autosomal-dominant neurodegenerative disease characterized by cognitive disturbance, motor abnormalities, and psychiatric symptoms. It is an orphan disease that is inherited genetically and results in progressive breakdown of the nerve cells. The disease impacts the person’s ability to move, think affecting the person psychologically.<\/p>\n

Huntington disease Pipeline Outlook  <\/strong><\/p>\n

A detailed picture of the Huntington’s Disease pipeline landscape is provided, which includes the disease overview and Huntington’s Disease treatment guidelines. The assessment part of the report embraces in-depth Huntington’s Disease commercial assessment and clinical assessment of the Huntington’s Disease pipeline products from the pre-clinical developmental phase to the marketed phase.<\/p>\n

At present, Huntington’s disease market has no effective treatment that can halt or delay the progression of the disease. Only FDA-approved drug involved to treat chorea associated with Huntington’s disease, which is the most notable known symptom, is Tetrabenazine (Xenazine), which is again a symptomatic approach to manage the disease.<\/p>\n

Request for sample pages<\/a><\/strong><\/p>\n

Huntington disease Pipeline<\/strong><\/p>\n

RG6042<\/strong> by Roche, Neflamapimod<\/strong> under development by Vertex and EIP pharma, Pepinemab<\/strong> of Vaccinex, SOM3355<\/strong> of OM Biotech SL and ALZ002<\/strong> of Allianz Pharma are some of the emerging pipeline products in the Huntington’s disease market.<\/p>\n

Several companies such as Hoffmann-La Roche<\/strong> (RG6042), EIP Pharma<\/strong> (Neflamapimod), Vaccinex<\/strong> (Pepinemab), and SOM Biotech SL<\/strong> (SOM3355) and others are in the process of developing multiple-stage products that have the potential to create a significant positive shift in the Huntington’s disease market Size.<\/p>\n

According to DelveInsight, Huntington’s Disease market in 7MM is expected to change in the study period 2017-2030.<\/strong><\/p>\n

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Visit to know more<\/a><\/p>\n

Report highlights<\/strong><\/p>\n